search
Back to results

Dry Eye Symptom Mitigation by Oral Intake of Probiotics

Primary Purpose

Dry Eye

Status
Recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Probiotics
Placebo
Sponsored by
Chung Shan Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dry Eye focused on measuring probiotics, dry eye, eye sore, eye strain

Eligibility Criteria

20 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: aged between 20 and 65 years with Schirmer's test results less than 10 mm or Ocular Surface Disease Index more than 25 Exclusion Criteria: evident ocular diseases such as cornea disease, cataract, vitreous degeneration, glaucoma, and retinopathy. diabetes hypertension or other chronic diseases or belong to vulnerable groups(pregnancy woman, prisoner, ethical minorities, economic or educationally disadvantaged subjects, disabled individuals such as those at terminal stage of tumorigenesis, blindness, terminal ill individuals)

Sites / Locations

  • Jen-Ai HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Control group

Treatment group

Arm Description

Subjects will take a capsule of containing microcrystalline cellulose per day for 35 days.

Subjects will take a capsule of containing Streptococcus thermophilus per day for 35 days.

Outcomes

Primary Outcome Measures

Change of Schirmer's Test Value from Baseline
The Schirmer's Test is used to assess tear secretion volume. The amounts of tears are measured in total millimeters after 5 minutes has elapsed. Lower measurement amount is regarded as a parameter of presence of dry eye disease.
Change of Tear Film Breakup Time from Baseline
Tear Break-Up Time is a measurement to reflect tear quality and is expressed in seconds. The shorter the Tear Break-Up Time, the poorer the tear film stability and quality. Lower measurement outcome (less than 10 seconds) is regarded as a parameter of presence of dry eye disease.
Ocular Surface Index Change from Baseline
Ocular Surface Index is assessed with fluorescein staining to reflect ocular surface damages. The staining scale ranges from 0 to 3, from milder to severe status, where grade 0 shows no staining, and grade 3 shows extensive staining.
Tear Osmolality Change from Baseline
Tear osmolality is used as a parameter of dry eye status.
Serum Biochemical Test
To determine the effects of oral probiotics intake on the contents of hyaluronic acid, sialic acid, and glutathione in the serum.

Secondary Outcome Measures

Ocular Surface Impression Cytology Change from Baseline
To assess the status of conjunctival goblet cells and epithelium.
Ocular Surface Disease Index Score Change from Baseline
A questionnaire is used to assess the health status on ocular surface, with higher scores indicating more severe status.
Intraocular Pressure Change from Baseline
To determine the effects of intervention on intraocular pressure.

Full Information

First Posted
May 19, 2023
Last Updated
June 14, 2023
Sponsor
Chung Shan Medical University
Collaborators
Nutrarex Biotech Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05906381
Brief Title
Dry Eye Symptom Mitigation by Oral Intake of Probiotics
Official Title
A Clinical Trial of Dry Eye Symptom Mitigation by Oral Intake of Probiotics
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 13, 2023 (Actual)
Primary Completion Date
August 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chung Shan Medical University
Collaborators
Nutrarex Biotech Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study investigates whether the oral intake of a probiotics capsule product may relieve dry eye symptoms. Participants will be aged between 20 - 65 years of age, with confirmed diagnosis of dry eye status. The participants will be assessed for several parameters and asked to take 1 probiotics capsule per day for 35 days. The parameters will include ocular surface health, tear volume, tear quality, intraocular pressure, tear osmolarity and serum biochemical test. After the 35 days are completed, the participants will be assessed again for the same parameters.
Detailed Description
This investigation is a randomized, double-blind study. Subjects with confirmed diagnosis of dry eye are randomly assigned to control group or treatment group, and asked to orally intake 1 capsule of either placebo or probiotics per day. All participants will be assessed for parameters, including intraocular pressure, ocular surface health, tear film breakup time (TBUT), tear volume (Schirmer's test), tear osmolarity, ocular surface impression cytology, ocular surface disease index (OSDI) and serum biochemical tests for quantification of hyaluronic acid, sialic acid, glutathione contents.The assessments are conducted at day1 for baseline and after the 35-day oral intake. The parameters are used to compare and evaluate whether the probiotics can relieve dry eye symptoms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye
Keywords
probiotics, dry eye, eye sore, eye strain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
88 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Subjects will take a capsule of containing microcrystalline cellulose per day for 35 days.
Arm Title
Treatment group
Arm Type
Experimental
Arm Description
Subjects will take a capsule of containing Streptococcus thermophilus per day for 35 days.
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotics
Intervention Description
A specific probiotics capsule product, containing Streptococcus thermophilus will be given to participants for oral intake for 35 days.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
A specific capsule product, containing microcrystalline cellulose will be given to participants for oral intake for 35 days.
Primary Outcome Measure Information:
Title
Change of Schirmer's Test Value from Baseline
Description
The Schirmer's Test is used to assess tear secretion volume. The amounts of tears are measured in total millimeters after 5 minutes has elapsed. Lower measurement amount is regarded as a parameter of presence of dry eye disease.
Time Frame
on baseline and day36
Title
Change of Tear Film Breakup Time from Baseline
Description
Tear Break-Up Time is a measurement to reflect tear quality and is expressed in seconds. The shorter the Tear Break-Up Time, the poorer the tear film stability and quality. Lower measurement outcome (less than 10 seconds) is regarded as a parameter of presence of dry eye disease.
Time Frame
on baseline and day36
Title
Ocular Surface Index Change from Baseline
Description
Ocular Surface Index is assessed with fluorescein staining to reflect ocular surface damages. The staining scale ranges from 0 to 3, from milder to severe status, where grade 0 shows no staining, and grade 3 shows extensive staining.
Time Frame
on baseline and day36
Title
Tear Osmolality Change from Baseline
Description
Tear osmolality is used as a parameter of dry eye status.
Time Frame
on baseline and day36
Title
Serum Biochemical Test
Description
To determine the effects of oral probiotics intake on the contents of hyaluronic acid, sialic acid, and glutathione in the serum.
Time Frame
on baseline and day36
Secondary Outcome Measure Information:
Title
Ocular Surface Impression Cytology Change from Baseline
Description
To assess the status of conjunctival goblet cells and epithelium.
Time Frame
on baseline and day36
Title
Ocular Surface Disease Index Score Change from Baseline
Description
A questionnaire is used to assess the health status on ocular surface, with higher scores indicating more severe status.
Time Frame
on baseline and day36
Title
Intraocular Pressure Change from Baseline
Description
To determine the effects of intervention on intraocular pressure.
Time Frame
on baseline and day36

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: aged between 20 and 65 years with Schirmer's test results less than 10 mm or Ocular Surface Disease Index more than 25 Exclusion Criteria: evident ocular diseases such as cornea disease, cataract, vitreous degeneration, glaucoma, and retinopathy. diabetes hypertension or other chronic diseases or belong to vulnerable groups(pregnancy woman, prisoner, ethical minorities, economic or educationally disadvantaged subjects, disabled individuals such as those at terminal stage of tumorigenesis, blindness, terminal ill individuals)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David Pei-Cheng Lin
Phone
886-910-371286
Email
pcl@csmu.edu.tw
First Name & Middle Initial & Last Name or Official Title & Degree
Chieh-Hung Yen
Phone
886-4-24819900
Email
chiehhungyen@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Pei-Cheng Lin
Organizational Affiliation
Chung Shan Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jen-Ai Hospital
City
Taichung
ZIP/Postal Code
412
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Pei-Cheng Lin, PhD
Phone
886-910-371286
Email
pcl@csmu.edu.tw
First Name & Middle Initial & Last Name & Degree
Chien-Hung Yen, MD
Phone
886-4-24819900
Email
chienhungyen@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
18040913
Citation
Herrero-Vanrell R, Peral A. [International Dry Eye Workshop (DEWS). Update of the disease]. Arch Soc Esp Oftalmol. 2007 Dec;82(12):733-4. doi: 10.4321/s0365-66912007001200002. No abstract available. Spanish.
Results Reference
background
PubMed Identifier
6712760
Citation
Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984 Apr;27(4):459-61. doi: 10.1002/art.1780270415. No abstract available.
Results Reference
background
PubMed Identifier
1203224
Citation
Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975 Nov;59(11):667-9. doi: 10.1136/bjo.59.11.667.
Results Reference
background
PubMed Identifier
25050925
Citation
Brito-Zeron P, Ramos-Casals M; EULAR-SS task force group. Advances in the understanding and treatment of systemic complications in Sjogren's syndrome. Curr Opin Rheumatol. 2014 Sep;26(5):520-7. doi: 10.1097/BOR.0000000000000096.
Results Reference
background
PubMed Identifier
10235562
Citation
Sullivan DA, Krenzer KL, Sullivan BD, Tolls DB, Toda I, Dana MR. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? Invest Ophthalmol Vis Sci. 1999 May;40(6):1261-5.
Results Reference
background
PubMed Identifier
18453777
Citation
Schrader S, Mircheff AK, Geerling G. Animal models of dry eye. Dev Ophthalmol. 2008;41:298-312. doi: 10.1159/000131097.
Results Reference
background
PubMed Identifier
28612893
Citation
Chisari G, Chisari EM, Francaviglia A, Chisari CG. The mixture of bifidobacterium associated with fructo-oligosaccharides reduces the damage of the ocular surface. Clin Ter. 2017 May-Jun;168(3):e181-e185. doi: 10.7417/T.2017.2002.
Results Reference
background

Learn more about this trial

Dry Eye Symptom Mitigation by Oral Intake of Probiotics

We'll reach out to this number within 24 hrs